Replies to post #10670 on Synaptogenix Inc (SNPX)

[XenaLives]

The TGA thinks the P2a was valid...

All that is needed is confirmation of previous results for provisional approval.

No safety issues. Cost is not an issue and the data will be for three different CNS indications so Drs will prescribe it for more than confirmed Alzheimer's.

When the Aussies approve it your opinion will be shown to be erroneous.

By the way, I never said the NTRP AD trial wouldn't pass the FDA's test. The FDA uses a trial format that hasn't been updated since the '40s, so who cares?